

DISCLOSURE OF TRANSFERS OF VALUE TO RECIPIENTS IN THE REPUBLIC OF IRELAND IN 2023

METHODOLOGICAL NOTE

General summary

In line with pharmaceutical industry practice, Octapharma Limited documents and declares transfers of value made to health professionals, other relevant decision makers, and health organisations in the Republic of Ireland. Details of transfers to recipients in the Republic of Ireland in the calendar year 2023 are provided on the website of Octapharma Ltd at www.octapharma.co.uk.

Recognition methodologies applied

Transfers of value qualifying for disclosure are identified during a payment review process. Each transfer of value is allocated to one of the value categories defined by the IPHA.

Indirect transfers of value to an individual via an organisation are allocated to the individual if the identity of the individual is known. If the identity of an individual is not known, the transfer is allocated to the organisation.

If the identity of an individual cannot be disclosed for legal reasons, the transfer of value is instead disclosed as part of an anonymised aggregate figure. The number of individuals within the aggregate is also disclosed, together with the percentage of all recipients that they represent.

Transfers of value for research and development made to individuals and organisations are disclosed as part of an anonymised aggregate figure for research and development.

Consent to disclose on a named basis

Each time an individual receives a transfer of value from Octapharma, a document is issued to them detailing the transfer and requesting confirmation of whether or not they consent to being named publicly as the recipient. If an individual does not consent, their transfer of value is disclosed as part of the anonymised aggregate figure.

Non-monetary transfers of value

Disclosure of non-monetary transfers are estimates of the equivalent value in monetary terms.

Multi-year contracts

Transfers of value are disclosed according to the date of transfer from Octapharma. Only value transferred by Octapharma in 2023 appears in the 2023 disclosure information.

Currency and VAT

Where a transfer has been made in a currency other than the Euro (EUR), the EUR equivalent has been determined using the average monthly exchange rate at the date of data preparation. Where VAT is charged, the total amount including VAT is disclosed.

Timing of transfers of value

Following a request for a transfer of value, transfers are made according to the usual practices of Octapharma's Finance Department.

Date of Preparation: 01 March 2024

Octapharma Limited
The Zenith Building
26 Spring Gardens
Manchester
M2 1AB

Office: +44 (0)161 837 3770
Fax: +44 (0)161 837 3799
Email: octapharma@octapharma.co.uk
Web: www.octapharma.co.uk